Conexeu Sciences Inc. (Nasdaq: CNXU), a biotechnology company focused on tissue regeneration, announced the opening of its new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. The facility is a purpose-built hub for leading life sciences companies.
The company commemorated the milestone with a ribbon-cutting ceremony on Tuesday, June 23, celebrating the next phase of its growth. Conexeu is among the first companies to operate within the 30,000-square-foot M4 Innovation Centre, which provides early-stage and scaling companies with specialized laboratory infrastructure, shared scientific resources, and a collaborative environment.
Advancing Regenerative Tissue Technologies
“This facility represents an important achievement for Conexeu and our mission to advance breakthrough regenerative tissue technologies,” said Dr. Claudia Chavez-Munoz, Co-Founder and Chief Scientific Officer. “We’re proud to be part of a growing life sciences ecosystem. Our work here will strengthen our research and development capabilities as we advance our research programs with the potential to improve outcomes for patients across tissue regeneration, wound care, and breast reconstruction.”
The new laboratory will serve as the center of Conexeu’s ongoing research, product development, and commercialization efforts. Work at the facility will include the advancement of the company’s proprietary CXU regenerative tissue platform and B.R.E.A.S.T., a novel 3D-bioprinted breast matrix designed to help the body regenerate natural tissue following mastectomy.
About Conexeu Sciences and the CXU Platform
Conexeu Sciences is a preclinical-stage regenerative tissue platform company. Its patented bioregenerative extracellular matrix (ECM) platform, CXU, is built on a single structural principle: one formula, one device, designed to scale across multiple addressable markets. The platform is designed to restore soft tissue lost through injury, aging, and GLP-1-associated tissue-related weight loss.
The company’s lead device candidate, Ten-Minute Tissue, is a unique thermosensitive ECM that remains fluid at room temperature and transitions to a stable gel in situ at body temperature within approximately ten minutes. In preclinical studies, Ten-Minute Tissue has demonstrated enhanced healing dynamics, organized scaffold formation, and a favorable low inflammatory profile, collectively supporting cell migration, proliferation, and differentiation, with tissue integration and new tissue formation.
Intellectual Property and Market Reach
The platform is grounded in more than a decade of university preclinical research and is protected by issued patents across the U.S., E.U., Japan, and Australia, with patent pending in Canada. Conexeu holds all rights, title, and interest in the platform IP, with no royalty or licensing obligations and full freedom to expand across new indications and markets.
